Document is current
Any future updates will be listed below
-
Authors
Jendle, Johan
Ilham, Sabrina
Alshannaq, Hamza
Matuoka, Jessica Y.
Pollock, Richard F.
Ahmed, Waqas
Norman, Gregory J.
-
Funding
Funding for this research was provided by:
Dexcom
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 9 October 2025
First Online: 1 November 2025
Declarations
:
: Richard F Pollock and Waqas Ahmed are full-time employees, and Richard F Pollock is a director and shareholder in, Covalence Research Ltd., which has received consulting fees from Dexcom for preparing this manuscript and from Dexcom outside the submitted work. Sabrina Ilham, Jessica Y. Matuoka, and Gregory J Norman are current employees of Dexcom. Hamza Alshannaq is a former employee of Dexcom, currently an employee of Neurocrine Biosciences Gregory J Norman and Jessica Y. Matuoka hold stock or stock options in Dexcom. Johan Jendle has received remuneration for participation in Advisory Boards or invited lectures from, Abbott Diabetes Care, Dexcom, Eli Lilly, Medtronic, NovoNordisk, Ypsomed, and Tandem. He also has received research support to his institution from Novo Nordisk and Medtronic.
: The analysis was based on previously conducted studies and did not contain any new studies involving human or animal participants that were performed by any of the authors.
